Loxo: III Trial of Fixed Pirtobrutinib + Vene and Rituximab vs Vene + Rituximab in CLL/SLL

Clinical Trial Grant

Duke Scholars

Principal Investigator Andrea Sitlinger Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Loxo Oncology, Inc.

Start Date

March 25, 2022

End Date

March 13, 2027

Administered By

Duke Cancer Institute

Awarded By

Loxo Oncology, Inc.

Start Date

March 25, 2022

End Date

March 13, 2027